Cargando…
Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
PURPOSE OF REVIEW: Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)] octreotate is an effective and safe second- or third-line treatment option for patients with low-grade advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN). In this review, we will focus on...
Autores principales: | Minczeles, N.S., Hofland, J., de Herder, W.W., Brabander, T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960621/ https://www.ncbi.nlm.nih.gov/pubmed/33721105 http://dx.doi.org/10.1007/s11912-021-01037-7 |
Ejemplares similares
-
New Directions in Imaging Neuroendocrine Neoplasms
por: Refardt, Julie, et al.
Publicado: (2021) -
Update on Histological Reporting Changes in Neuroendocrine Neoplasms
por: Bräutigam, Konstantin, et al.
Publicado: (2021) -
The Role of Patient Support Groups in Neuroendocrine Neoplasms
por: Kolarova, Teodora, et al.
Publicado: (2021) -
New Developments in Gastric Neuroendocrine Neoplasms
por: Exarchou, Klaire, et al.
Publicado: (2022) -
Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation?
por: Cope, Jack, et al.
Publicado: (2022)